国际共识:炎症性肠病临床试验中肠屏障评估与治疗效果
该国际共识由12名专家采用改良德尔菲法,基于系统文献综述形成的声明进行匿名投票,共识阈值定义为至少75%同意。共识为未来评估恢复肠屏障完整性和/或功能疗法的临床试验提供了结构化框架。
要点
- 共识推荐肠屏障评估可作为IBD临床试验的终点指标。
- 共识明确了肠屏障重新评估的时机及方案要求。
- 共识对影像、通透性检测和生物标志物等评估工具提出标准化建议。
核心结论
- 该国际共识为未来评估恢复IBD肠屏障完整性和/或功能疗法的临床试验提供了结构化框架。
研究设计与样本
- 由12名国际专家组成的小组,基于系统文献综述形成的声明,采用改良德尔菲法进行讨论和匿名投票。
- 共识预先定义为参与者至少75%同意,研究按照德尔菲研究实施与报告框架进行。
主要发现
- 声明涉及临床试验设计的关键方面,包括肠屏障评估作为终点指标的作用、重新评估的时机、方案要求及疾病特异性考虑。
- 其他声明聚焦于肠屏障评估工具的选择与标准化,涵盖基于影像的技术、功能性通透性检测和內源性生物标志物,以及实施考虑和未来研究方向。
关键数值与推荐
- 共识阈值:至少75%的参与者同意。
临床怎么用
- 为设计评估恢复IBD肠屏障完整性和/或功能疗法的临床试验提供结构化指导。
- 建议在试验中考虑将肠屏障评估作为终点指标,并关注重新评估时机和方案要求。
- 推荐对影像技术、功能性通透性检测和內源性生物标志物等评估工具进行标准化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Restoration of intestinal barrier integrity and function in inflammatory bowel disease (IBD) has been associated not only with a reduced burden of persistent symptoms but also with improved long-term outcomes, prompting growing interest in intestinal barrier healing as a potential new therapeutic target. To date, no clinical trials have specifically evaluated therapies aimed at restoring intestinal barrier function in IBD, and there is currently no consensus on how such trials should be designed or how the intestinal barrier should be assessed. The aim of this initiative was to develop consensus recommendations on the optimal design of clinical trials and the selection of tools to evaluate therapies targeting the intestinal barrier in IBD. METHODS: A panel of 12 international specialists with recognised expertise in the intestinal barrier and/or IBD clinical trials evaluated statements developed from a systematic literature review. Statements were discussed and anonymously voted on using a modified Delphi methodology. Consensus was predefined as at least 75% agreement among participants. The study was conducted and reported in accordance with the Conducting and REporting of DElphi Studies framework. RESULTS: Fourteen statements reached consensus and were approved. These statements addressed key aspects of clinical trial design, including the role of intestinal barrier assessment as an endpoint, timing of reassessment, protocol requirements and disease-specific considerations. Additional statements focused on the selection and standardisation of tools for intestinal barrier assessment, encompassing imaging-based techniques, functional permeability assays and endogenous biomarkers, as well as considerations for implementation and future research directions. CONCLUSIONS: This international consensus provides a structured framework to guide the design of future clinical trials evaluating efficacies of therapies in restoring intestinal barrier integrity and/or function in IBD.
引用
- Vieujean S, Atreya R, Buda A, et al. International consensus on intestinal epithelial barrier assessment and therapeutic effects in inflammatory bowel diseases clinical trials. Gut. 2026. PMID: 42463422. doi:10.1136/gutjnl-2026-339056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。